Hints and tips:
...In sellside, Bernstein likes Campari. Sector note....
...“It takes a long time to admit you’re not a growth company any more,” says Ali Dibadj of Bernstein. “It’s getting to that point.”...
...A 2009 Supreme Court case involving prescription drug labels, Wyeth v Levine, greenlighted state laws that are stricter than federal laws....
...“The most plausible explanation is a China Inc deal,” says a research note from Bernstein in Hong Kong, noting that a number of other Chinese companies have been stopped by Chinese regulators from going...
...In 1996, a landmark ruling in the case of Bernstein v. Department of Justice established that computer code was free speech, protected under the First Amendment of the US Constitution....
...This article has been amended since first publication to show correct figures for the chart labelled “Traditional v online TV”. Back to the top of the page...
...Some would like to restart where the industry was forced to halt in 2009 with the last wave of mergers, such as Pfizer’s $68bn acquisition of Wyeth....
...Bernstein....
...the Analysts, Martoma claimed to have “black edge” —illicit, nonpublic information… The Analysts exchanged a number of emails and instant messages with Cohen about whether Martoma’s advice on Elan and Wyeth...
...Bernstein valued Pfizer’s consumer portfolio at about £9bn....
...In the longer term, the effects of this verdict on Samsung’s brand and reputation will be the key things to watch, argues Mark Newman, an analyst at Sanford C Bernstein....
...“Even though this swift exodus may soon be followed by a ‘V’ shaped recovery, should a resolution be forthcoming, a lot of technical damage has already been done,” he added....
...Admittedly, with age came the unveiling of Carl Bernstein, Bob Woodward and Ben Bradlee in their human, fallible and – Bradlee aside – slightly frumpy reality, but it didn’t matter....
...“The Wyeth/Pfizer business would in some ways be a perfect strategic fit for Heinz because it is so focused in emerging markets,” Alexia Howard, analyst at Bernstein Research, said last month....
...In a research note, Bernstein cautioned of “persistent over-optimism” in genomics, Illumina’s area of expertise, which has only proved to have limited use in many genetically complex common diseases....
...Yet, continuing to spend without being able to demonstrate adequate returns necessitates action,” said Bernstein in a research note....
...He added that the company was still digesting the Wyeth deal....
...Tim Anderson, with Sanford Bernstein, said: “I think he was pushed. This was very sudden. But when does the board itself take responsibility?”...
...Tim Anderson, pharmaceuticals analyst at Sanford Bernstein, wrote recently that Pfizer had become “the poster child for inefficient R&D”....
...Tim Anderson from Bernstein said Pfizer’s stock was inexpensive when compared to the earnings multiples of its peers, but cautioned: “One of our longer-term concerns … is that it may be caught in a perpetual...
...He remembers uncapping a black marker to write: R squared over A is V+, in what he calls a type of epiphany....
...Tim Anderson from Bernstein Research said: “[Pfizer] essentially has no realistic way of replacing the many drugs that are scheduled to go generic apart from doing a mega-merger.”...
...Bernstein Research, an investment house, recently dubbed the short-term impact as small enough to be “nearly a rounding error to earnings per share”....
...Crucell would offer Wyeth a chance to maintain its weight and to diversify its portfolio....
International Edition